Raj Maturi, MD

Exploring sirolimus as potential alternative therapy for persistent AMDAnti-vascular endothelial growth factor (VEGF) therapy is highly successful, but as Raj Maturi, MD, pointed out, also has some limitations.
Sirolimus shows promise for posterior segment non-infectious uveitisIntravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.
Combined steroids, anti-VEGFs show promise in DMEFor some patients with diabetic macular edema, treatment with anti-vascular endothelial growth factor agents may not be enough. Clinicians need to consider other options, including dexamethasone implants.